AbbVie Financial Statements (ABBV)
|
|
|
|
Report date
|
|
|
21.02.2020 |
19.02.2021 |
18.02.2022 |
17.02.2023 |
20.02.2024 |
|
04.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
33 266 |
45 804 |
56 197 |
58 054 |
54 318 |
|
53 542 |
|
Operating Income, bln rub |
|
|
12 983 |
11 363 |
17 924 |
18 117 |
12 757 |
|
14 076 |
|
EBITDA, bln rub |
? |
|
16 264 |
21 148 |
28 280 |
31 424 |
26 358 |
|
24 572 |
|
Net profit, bln rub |
? |
|
7 882 |
4 616 |
11 542 |
11 836 |
4 863 |
|
5 675 |
|
|
OCF, bln rub |
? |
|
13 324 |
17 588 |
22 777 |
24 943 |
22 839 |
|
11 758 |
|
CAPEX, bln rub |
? |
|
552.0 |
798.0 |
787.0 |
695.0 |
777.0 |
|
683.0 |
|
FCF, bln rub |
? |
|
12 772 |
16 790 |
21 990 |
24 248 |
22 062 |
|
11 075 |
|
Dividend payout, bln rub
|
|
|
6 366 |
7 716 |
9 261 |
10 043 |
10 539 |
|
8 273 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
80.8% |
167.2% |
80.2% |
84.9% |
216.7% |
|
145.8% |
|
|
OPEX, bln rub |
|
|
12 459 |
17 856 |
19 865 |
21 826 |
24 835 |
|
25 604 |
|
Cost of production, bln rub |
|
|
7 439 |
15 387 |
17 446 |
17 414 |
8 780 |
|
12 551 |
|
R&D, bln rub |
|
|
6 407 |
6 557 |
7 084 |
6 510 |
8 453 |
|
7 797 |
|
Interest expenses, bln rub |
|
|
1 784 |
2 454 |
2 423 |
2 230 |
2 224 |
|
2 430 |
|
|
Assets, bln rub |
|
|
89 115 |
150 565 |
146 529 |
138 805 |
134 711 |
|
143 422 |
|
Net Assets, bln rub |
? |
|
-8 172 |
13 076 |
15 408 |
17 254 |
10 360 |
|
6 032 |
|
Debt, bln rub |
|
|
66 728 |
86 056 |
76 684 |
63 271 |
59 385 |
|
71 079 |
|
Cash, bln rub |
|
|
39 924 |
8 479 |
9 830 |
9 229 |
12 816 |
|
7 285 |
|
Net debt, bln rub |
|
|
26 804 |
77 577 |
66 854 |
54 042 |
46 569 |
|
63 794 |
|
|
Ordinary share price, rub |
|
|
88.5 |
107.2 |
135.4 |
161.6 |
155.0 |
|
143.5 |
|
Number of ordinary shares, mln |
|
|
1 481 |
1 667 |
1 770 |
1 771 |
1 768 |
|
1 769 |
|
|
Market cap, bln rub |
|
|
131 128 |
178 619 |
239 658 |
286 211 |
273 987 |
|
253 816 |
|
EV, bln rub |
? |
|
157 932 |
256 196 |
306 512 |
340 253 |
320 556 |
|
317 610 |
|
Book value, bln rub |
|
|
-42 425 |
-102 924 |
-92 922 |
-82 341 |
-77 543 |
|
-95 909 |
|
|
EPS, rub |
? |
|
5.32 |
2.77 |
6.52 |
6.68 |
2.75 |
|
3.21 |
|
FCF/share, rub |
|
|
8.62 |
10.1 |
12.4 |
13.7 |
12.5 |
|
6.26 |
|
BV/share, rub |
|
|
-28.6 |
-61.7 |
-52.5 |
-46.5 |
-43.9 |
|
-54.2 |
|
|
EBITDA margin, % |
? |
|
48.9% |
46.2% |
50.3% |
54.1% |
48.5% |
|
45.9% |
|
Net margin, % |
? |
|
23.7% |
10.1% |
20.5% |
20.4% |
8.95% |
|
10.6% |
|
FCF yield, % |
? |
|
9.74% |
9.40% |
9.18% |
8.47% |
8.05% |
|
4.36% |
|
ROE, % |
? |
|
-96.5% |
35.3% |
74.9% |
68.6% |
46.9% |
|
94.1% |
|
ROA, % |
? |
|
8.84% |
3.07% |
7.88% |
8.53% |
3.61% |
|
3.96% |
|
|
P/E |
? |
|
16.6 |
38.7 |
20.8 |
24.2 |
56.3 |
|
44.7 |
|
P/FCF |
|
|
10.3 |
10.6 |
10.9 |
11.8 |
12.4 |
|
22.9 |
|
P/S |
? |
|
3.94 |
3.90 |
4.26 |
4.93 |
5.04 |
|
4.74 |
|
P/BV |
? |
|
-3.09 |
-1.74 |
-2.58 |
-3.48 |
-3.53 |
|
-2.65 |
|
EV/EBITDA |
? |
|
9.71 |
12.1 |
10.8 |
10.8 |
12.2 |
|
12.9 |
|
Debt/EBITDA |
|
|
1.65 |
3.67 |
2.36 |
1.72 |
1.77 |
|
2.60 |
|
|
R&D/CAPEX, % |
|
|
1 161% |
821.7% |
900.1% |
936.7% |
1 088% |
|
1 142% |
|
|
CAPEX/Revenue, % |
|
|
1.66% |
1.74% |
1.40% |
1.20% |
1.43% |
|
1.28% |
|
| AbbVie shareholders |
